Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.
about
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentLp-PLA2 Inhibition-The Atherosclerosis Panacea?Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and CaucasiansClinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.Racial variation in lipoprotein-associated phospholipase A₂ in older adults.Life course socioeconomic position is associated with inflammatory markers: the Framingham Offspring Study.Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.Vascular effects of the red blood cell storage lesionAssociation of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population.Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemiaLipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.Anti-oxidant properties of high-density lipoprotein and atherosclerosisTaiwanese female vegetarians have lower lipoprotein-associated phospholipase A2 compared with omnivores.The emerging roles of PAF acetylhydrolase.Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosisShort-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitusSystematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and AtherosclerosisPLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European AncestryModulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study.Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.HDL is the major lipoprotein carrier of plasma F2-isoprostanes.Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular diseaseBiomarkers of atherosclerosis: clinical applicationsCardiovascular disease risk prediction in women: is there a role for novel biomarkers?White blood cell count predicts all-cause mortality in patients with suspected peripheral arterial diseaseBaseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.Role of secretory phospholipase A₂ in women with metabolic syndrome.Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia.Recent developments with lipoprotein-associated phospholipase A2 inhibitors.
P2860
Q24634492-16052F82-EB31-4B1F-83AC-F14E5510595FQ33664272-627B3CD9-FB0E-4365-8E23-5C955E2E2D0DQ33764961-CF8379E1-60DA-4E4E-82D9-EEE95172229BQ33829154-892AC63D-75F3-4831-8B2C-D8F4F3D1F581Q33849524-CC3962ED-81CC-4DB1-B1E4-80F8A79889E5Q33944562-E092D448-2923-42B5-857A-A56923965B83Q33946023-D2F36C01-371C-432C-8E61-53E37423E97FQ33955821-352F58D3-3697-4549-B617-7DCA62A43944Q34016317-8E84F4B5-C7CB-47AF-B7D0-ECE8CFF1A7F3Q34029776-528D6FB9-1FA3-4F6D-8823-13953E0DA857Q34037051-AE5FB842-425B-417A-99DA-4F40A29530D4Q34188093-D504FD6E-8EBA-47C8-AB26-F8574BBA1A7BQ34214336-3100E12A-94C0-4A19-B20D-E3A30C0A9286Q34440172-BC384D4D-F01D-4D9C-992E-0B416A19C124Q34474519-64F18E58-CBB9-43E2-9E05-71F7F40FD011Q34847192-A38F6113-1596-4EDD-ACD4-B187CF13B19DQ34890672-F84F90E6-7699-44EE-BF67-88B2E780EE7BQ34960396-A7B3689C-BEED-469B-A7B9-8CD3F54895D8Q35006841-F0AA06F3-8F76-4B0E-9360-DFDFB11F2037Q35111638-53A8A4ED-3E9A-442D-AD50-41A0D85E9404Q35520145-5301D082-FFD5-4B36-9330-84F5ED3C8F0CQ35764402-AB6905D2-343C-4B85-A0F2-1E44F7862BA0Q36041389-A2E8FC6B-1F8B-457A-9F8E-45CA3C6E27B5Q36145180-20BB31D2-0539-4A09-814F-10A864EC07E5Q36368459-681D1981-64F2-401E-80F1-0C4E26497EFDQ36632984-8D7F5D25-64FA-4A37-9C32-8D66252A8481Q36808689-62F10F16-10CB-443B-A508-B1F7C6A9A8CCQ36835900-52239814-0FA1-4A87-A4E9-2CBEB032D2D4Q37130810-4CED25F7-70A8-49D1-A7C9-BDA98DDB65E3Q37210477-A8981223-4294-42F6-B9B1-BD345A7B718FQ37299885-54B33A7B-3BE1-4B10-9475-EC8B931D884EQ37305341-40D3B58E-315C-4D8D-9BF9-ACECE22DAD6DQ37307999-B980C69B-A002-4FBE-BD46-3E42B874DC39Q37424605-D3E67247-47E6-4684-BF27-60427BDD513DQ37445745-7AE20A92-F715-42AC-8399-3F85216356F7Q37685077-50A36908-F7C3-4805-940D-190E00EFEC45Q37690826-5986B99D-59ED-49F0-A97B-C1D1CFC89E1EQ37720776-C8CE236F-C83B-4E99-87F2-04BC33E667EDQ37733099-E711F85F-E950-4EA8-ADA7-D95B81493698Q37738359-6F01C558-96E5-473D-AE6E-7FBFFF2AA5EA
P2860
Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Association between lipoprotei ...... disease: a systematic review.
@ast
Association between lipoprotei ...... disease: a systematic review.
@en
type
label
Association between lipoprotei ...... disease: a systematic review.
@ast
Association between lipoprotei ...... disease: a systematic review.
@en
prefLabel
Association between lipoprotei ...... disease: a systematic review.
@ast
Association between lipoprotei ...... disease: a systematic review.
@en
P2093
P356
P1476
Association between lipoprotei ...... disease: a systematic review.
@en
P2093
Carolina A Garza
Francisco Lopez-Jimenez
Iftikhar J Kullo
Joseph P McConnell
Virend K Somers
P304
P356
10.4065/82.2.159
P407
P577
2007-02-01T00:00:00Z